TP53 and ovarian carcinoma: To fill the above gaps, we studied the role of PANDAR in cisplatin sensitivity and discovered that cisplatin-induced PANDAR expression counter-regulates nuclear p53 and its phosphorylation at Ser15 via interacting with SFRS2, which in turn, attenuates cisplatin sensitivity in ovarian cancer chemotherapy.